Study of Cemiplimab Use in Hepatocellular Carcinoma Meets Primary End Points
Thomas Marron, PhD, MD, discusses the end points of an exploratory study which examines the use of cemiplimab in hepatocellular carcinoma.
Timing of Immunotherapy Discontinuation Remains Challenging in Melanoma
Thomas Marron, MD, discusses the rationale for investigating immunotherapy discontinuation in patients with melanoma.